Drug Search Results
More Filters [+]

ACT-281959

Alternative Names: act-281959, act281959, act 281959
Latest Update: 2018-07-10
Latest Update Note: Clinical Trial Update

Product Description

a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. A prodrug for ACT-246475 (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26550844/)

Mechanisms of Action: P2Y12 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Idorsia
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ACT-281959

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AC-075-101

P1

Completed

Healthy Volunteers

2012-03-01

28%

Recent News Events

Date

Type

Title